These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30917871)

  • 41. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
    Iacovelli R; De Giorgi U; Galli L; Zucali P; Nolè F; Sabbatini R; Fraccon AP; Basso U; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Pasini F; Masini C; Massari F; Buti S; Sava T; Sacco C; Ricotta R; Sperduti I; Tortora G; Porta C
    Clin Genitourin Cancer; 2018 Oct; 16(5):355-359.e1. PubMed ID: 29803346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience.
    Birkhäuser FD; Pantuck AJ; Rampersaud EN; Wang X; Kroeger N; Pouliot F; Zomorodian N; Riss J; Li G; Kabbinavar FF; Belldegrun AS
    Cancer J; 2013; 19(3):189-96. PubMed ID: 23708063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies.
    Kroeger N; Li H; De Velasco G; Donskov F; Sim HW; Stühler V; Wells JC; Stukalin I; Heide J; Bedke J; Agarwal N; Parekh H; Rini BI; Knox JJ; Pantuck A; Choueiri TK; Chin Heng DY
    Clin Genitourin Cancer; 2019 Feb; 17(1):65-71. PubMed ID: 30341028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.
    Lam ET; Wong MK; Agarwal N; Redman BG; Logan T; Gao D; Flaig TW; Lewis K; Poust J; Monk P; Jarkowski A; Sendilnathan A; Bolden M; Kuzel TM; Olencki T
    J Immunother; 2014 Sep; 37(7):360-5. PubMed ID: 25075565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
    Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
    Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
    Numakura K; Kobayashi M; Muto Y; Sekine Y; Takahashi M; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Nanjyo H; Habuchi T
    Sci Rep; 2020 Nov; 10(1):20089. PubMed ID: 33208816
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
    Ramaswamy A; Joshi A; Noronha V; Patil VM; Kothari R; Sahu A; Kannan RA; Sable N; Popat P; Menon S; Prabhash K
    Clin Genitourin Cancer; 2017 Jun; 15(3):e345-e355. PubMed ID: 28077238
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.
    Bamias A; Tzannis K; Beuselinck B; Oudard S; Escudier B; Diosynopoulos D; Papazisis K; Lang H; Wolter P; de Guillebon E; Stravodimos K; Chrisofos M; Fountzilas G; Elaidi RT; Dimopoulos MA; Bamia C
    Br J Cancer; 2013 Jul; 109(2):332-41. PubMed ID: 23807171
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implications of therapy choice on overall survival in metastatic renal cell carcinoma: a single institution experience.
    Parmar S; Rademaker AW; Fung BB; Kozlowski JM; Kuzel TM
    Med Oncol; 2005; 22(4):399-405. PubMed ID: 16260858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
    Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
    Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
    Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
    BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
    Rebuzzi SE; Signori A; Buti S; Banna GL; Murianni V; Damassi A; Maruzzo M; Giannarelli D; Tortora G; Galli L; Rizzo M; De Giorgi U; Antonuzzo L; Bracarda S; Cartenì G; Atzori F; Tamberi S; Procopio G; Fratino L; Lo Re G; Santoni M; Baldessari C; Astone A; Calabrò F; Brunelli M; Porta C; Rescigno P; Basso U; Fornarini G
    ESMO Open; 2022 Dec; 7(6):100634. PubMed ID: 36493602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study.
    Massari F; Di Nunno V; Guida A; Costa Silva CA; Derosa L; Mollica V; Colomba E; Brandi G; Albiges L
    Clin Genitourin Cancer; 2021 Feb; 19(1):32-40. PubMed ID: 32694008
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
    Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
    Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.